FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2019/07/020388 [Registered on: 26/07/2019] Trial Registered Prospectively
Last Modified On: 13/01/2026
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Radionuclide Therapy and chemotherapy]  
Study Design  Other 
Public Title of Study   The study aims at comparing the efficacy of radio-isotope therapy (Lutetium-177 PRRT) alone and combination therapyof radio-isotope and chemotherapy in neuroendocrine tumors which show somatostatin and glucose receptor expression. 
Scientific Title of Study   PReCedeNT trial: Phase III randomised-controlled open-label trial of Lutetium - 177 Peptide Receptor Radionuclide Therapy (PRRT) Plus Chemotherapy Versus PRRT alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs) 
Trial Acronym  PReCedeNT 
Secondary IDs if Any    
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Ameya Puranik 
Designation  Assistant professor and nuclear medicine  
Affiliation  Tata Memorial Hospital  
Address  Department of nuclear medicine and molecular imaging room no 52 basement main building Dr Ernest Borges Marg Parel Mumbai

Mumbai
MAHARASHTRA
400012
India 
Phone  9619811125  
Fax    
Email  ameya2812@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Ameya Puranik 
Designation  Assistant professor and nuclear medicine  
Affiliation  Tata Memorial Hospital  
Address  Department of nuclear medicine and molecular imaging room no 52 basement main building Dr Ernest Borges Marg Parel Mumbai

Mumbai
MAHARASHTRA
400012
India 
Phone  9619811125  
Fax    
Email  ameya2812@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Ameya Puranik 
Designation  Assistant professor and nuclear medicine  
Affiliation  Tata Memorial Hospital  
Address  Department of nuclear medicine and molecular imaging room no 52 basement main building Dr Ernest Borges Marg Parel Mumbai

Mumbai
MAHARASHTRA
400012
India 
Phone  9619811125  
Fax    
Email  ameya2812@gmail.com  
 
Source of Monetary or Material Support  
Intramural Tata memorial Hospital 3rd floor main building Dr Ernest borges Marg parel Mumbai 400012 
 
Primary Sponsor  
Name  Tata Memorial Hospital  
Address  Dr Ernest Borges Marg Parel Mumbai 400012 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Ameya Puranik  Tata Memorial Hospital   Department of nuclear medicine and molecular imaging room no 52 basement main building Dr Ernest Borges Marg Parel Mumbai
Mumbai
MAHARASHTRA 
9619811125

ameya2812@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Commitee   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C269||Malignant neoplasm of ill-definedsites within the digestive system,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Arm B Peptide Receptor Radionuclide Therapy   Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE, 180-200 mCi administered intravenously for 4 cycles, at interval duration of 8-12 weeks 
Intervention  Peptide Receptor Radionuclide Therapy plus Chemotherapy   Arm A Peptide Receptor Radionuclide Therapy plus Chemotherapy Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE, 180-200 mCi administered intravenously for 4 cycles, at interval duration of 6-8 weeks Plus CAP-TEM Protocol: Day 1: Oral Capecitabine 1500 mg/m2, per oral, twice daily within 15 min of food for 14 days, followed by 2 week rest period Day 10-D14: Oral Temozolomide 20 mg/m2 per oral, daily dose for 5 days as a single dose with a glass of water at bed time. To be taken empty stomach at least 30 min before or 2 hours after meal.  
 
Inclusion Criteria  
Age From  19.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  1. Histopathological diagnosis of GEP-NET
necessarily satisfying all the the criteria
below
2. Well differentiated G2 Ki67 more than 5-20%
and G3 ki67- greater than 20-55%
3. Well-differentiated G1 and G2 2 to5% with
disease progression in last 6 months
4. Positive Ga68 DOTANOC PETCT - Krennings
score more than equal to 3
5. Positive FDG PET imaging, grade 3 or 4 uptake
6.Locally advanced or inoperable disease or
metastatic disease
7. Karnofsky performance-status score of at
least 60 or ECOG performance status less
than or equal to 2
8. Life expectancy greater than 6 months
 
 
ExclusionCriteria 
Details  1. Serum creatinine level of more than 1.6 mg
per dl or a creatinine clearance of less
than 50 ml per min
2. Hemoglobin level of less than 8.0 g per
deciliter
3. Red blood cell count not less than
300,000 per cubic millimeter
4. White cell count of less than 2000 per cubic
millimeter
5. Platelet count of less than 75,000 per cubic
millimetre
6. Total bilirubin level of more than 3 times
the upper limit of the normal range
7. Serum albumin level more than 3.0 g per dl
8. Treatment with more than 30 mg of octreotide
LAR within 12 weeks before randomisation
9. Peptide receptor radionuclide therapy at any
time before randomisation
10.Pregnancy and Lactation
11.Patients with concurrent malignancies

 
 
Method of Generating Random Sequence   Other 
Method of Concealment   On-site computer system 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Progression-free survival (PFS) is defined as the time duration from the date of randomization to the tumor progression or death from any cause. Patients alive at last follow-up will be censored at the date of last follow-up visit  8 years  
 
Secondary Outcome  
Outcome  TimePoints 
-Objective Tumor Response
-Quality of Life parameters  
8 years 
 
Target Sample Size   Total Sample Size="162"
Sample Size from India="162" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   06/08/2019 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="8"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Open to Recruitment 
Recruitment Status of Trial (India)  Closed to Recruitment of Participants 
Publication Details   Nil 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

Synopsis

 

Scientific background and rationale

Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies ranging from well-differentiated, slowly growing tumors to poorly differentiated neoplasms, which are aggressive and less frequent (1). Neuroendocrine cells have the ability to express several peptide receptors in high volumes, especially somatostatin receptors, which are heptahelical G-protein–coupled glycoprotein transmembrane receptors. In the most recent SEER register (SEER-17), more than half of all NETs, i.e. 61%, were gastroenteropancreatic neuroendocrine tumors (GEP-NETs), with the highest frequency being found in the rectum (17.7%), the small intestine (17.3%), and the colon (10.1%) [2]. The tumor biology varies with the location of the primary tumors as well as with the grade and staging of the tumors. The malignant potential ranges from the most benign types of tumor to small intestinal tumors and up to neuroendocrine carcinoma (NEC) with very malignant behavior [3]. The tumors are graded according to the classification system of the World Health Organization (WHO), wherein a new classification system is just being accepted. The tumors are divided into grade 1 NET (NET-G1), with a proliferation <3%, NET-G2 with a proliferation between 3 and 20%, NET-G3, which is a new group with a Ki-67 >20%, and finally NEC-G3, exhibiting a Ki-67 of >20% as well (unpublished data). Of note, the difference between NET-G3 and NEC-G3 is mainly the degree of differentiation. NET-G3 are well-differentiated tumors, often with expression of somatostatin receptors. NEC-G3 are poorly differentiated tumors that usually lack expression of somatostatin receptors.

NETs are characterized by a general lack of symptoms until they are in advanced phase, and early biomarkers are not as available and useful as required. Heterogeneity is an intrinsic, pivotal feature of NETs that derives from diverse causes and ultimately shapes tumor fate.(4) The different layers that conform NET heterogeneity include a wide range of distinct characteristics, from the mere location of the tumor to its clinical and functional features, and from its cellular properties, to the core signaling and (epi)genetic components defining the molecular signature of the tumor. The importance of this heterogeneity resides in that it translates into a high variability among tumors and, hence, patients, which hinders a more precise diagnosis and prognosis and more efficacious treatment of these diseases.

Heterogeneity can be assessed objectively by molecular imaging techniques. Patients with well-differentiated GEP NETs undergo imaging with Ga-68-DOTATOC PET/CT (DOTA PET/CT), which is somatostatin-receptor (SSTR)-specific imaging tracer. PET/CT with  68Ga-DOTA-peptides has been reported to present a higher sensitivity for the detection of well-differentiated, less aggressive NETs than CT or scintigraphy (5,6). On the other hand, 18F-FDG PET/CT is preferred for more aggressive, less differentiated NETs as there is emerging evidence that the presence of increased expression of GLUT (glucose-transporter) receptors in NETs highlights an increased propensity for invasion and metastasis, and an overall poorer prognosis (7). In fact, a strong association has recently been shown between higher 18F-FDG uptake and worse outcome even in patients with well-differentiated or low-grade tumors, with provision of prognostic information independently of the mitotic rate (8). Accordingly, 18F-FDG has an important role in managing patients with NETs because of its high prognostic value and its higher sensitivity in delineating disease extent, especially in aggressive and high-grade and aggressive intermediate-grade tumors (9). While DOTA PET avidity is a feature of well-differentiated disease, FDG avidity tends to be associated with more aggressive, de-differentiated disease (10). Grade 1 NET tend to be DOTA-avid but negative on FDG PET, whereas grade 3 NEC generally show the opposite imaging phenotype. Grade 2 NET may demonstrate uptake of both tracers. Irrespective of pathological grade, the distribution of these tracers may not be spatially concordant, with some lesions having either DOTA or FDG avidity, but not both. This highlights the limitations of relying on histopathological grade from a single biopsy site to predict disease behaviour. Despite the prognostic utility of pathological grading, FDG PET positivity has been consistently shown to be independently associated with a poor prognosis. (11)

SSTR expression on the surface of NET enables the use of somatostatin analogues labelled with particle-emitting radionuclides for targeted peptide receptor radionuclide therapy (PRRT)

NETTER-1 trial has established Lu-177 PRRT (Peptide Receptor Radionuclide Therapy) as standard of care in treatment of metastatic well-differentiated GEP NETs.(12) However, FDG positivity in these tumors suggests presence of aggressive phenotypes and warrants simultaneous use of chemotherapy.(13) Strosberg et.al, (14) have shown exceptionally high and durable response rate with combination of capecitabine and temozolomide in metastatic well, or moderately differentiated pancreatic neuroendocrine tumor. Combination of PRRT and chemotherapy, that is, temozolomide-capecitabine (CAP-TEM) has been therefore effective in patients showing SSTR and GLUT receptor expression on Ga-68 DOTA PET and FDG PET respectively.(15) Kong et al studied a retrospective cohort of 52 patients selected for treatment on the basis of somatostatin-receptor imaging without spatially discordant FDG-avid disease. All patients received conventional PRRT regime, in addition oral capecitabine was added after every PRRT cycle. Clinical, biochemical and imaging response was assessed after completion of induction treatment of combination of PRRT and chemotherapy. Combination of PRRT and chemotherapy was well tolerated with negligible grade 3/4 toxicities. After a median follow-up period of 36 months, the median OS was not achieved with a median PFS of 48 months. At 3 months after completion of combination of PRRT and chemotherapy, 2% of patients showed a complete anatomical response, 28% a partial response, 68% stable disease, and only 2% progression. On FDG PET/CT, 27% achieved a complete metabolic response during the follow-up period. A biochemical response (>25% fall in chromogranin-A levels) was seen in 45%. (16) These results established the effectiveness of combination of PRRT and chemotherapy which is now practiced routinely. However, there is no prospective study to establish this treatment regime. We therefore propose to prospectively evaluate combination of PRRT and chemotherapy in patients with well-differentiated NETs, in  systematic manner to generate reliable conclusion with regards to this treatment regimen for intermediate to high grade NETs.

Study design Type of study - Prospective, randomized, open-label ,Patient number - 162

●       Arm A (PRRT Arm)

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE, 180-200 mCi administered intravenously for 4 cycles, at interval duration of 8-12 weeks

●       Arm B (PRRT plus Chemotherapy Arm)

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE, 180-200 mCi administered intravenously for 4 cycles, at interval duration of 6-8 weeks

Plus

CAP-TEM Protocol:

Day 1: Oral Capecitabine 1500 mg/m2, per oral, twice daily within 15 min of food for 14 days, followed by 2 week rest period

Day 10-D14: Oral Temozolomide 20 mg/m2 per oral, daily dose for 5 days as a single dose with a glass of water at bed time. To be taken empty stomach at least 30 min before or 2 hours after meal.

 
Close